Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel
NASDAQ:SNOA

Sonoma Pharmaceuticals 6/17/2024 Earnings Report

Sonoma Pharmaceuticals logo
$1.15 -0.03 (-2.54%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$1.15 0.00 (0.00%)
As of 07:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Sonoma Pharmaceuticals EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sonoma Pharmaceuticals Revenue Results

Actual Revenue
$3.44 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sonoma Pharmaceuticals Announcement Details

Quarter
Date
6/17/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Sonoma Pharmaceuticals' next earnings date is estimated for Wednesday, July 15, 2026, based on past reporting schedules.

Conference Call Resources

Sonoma Pharmaceuticals Earnings Headlines

What's going on with Sonoma Pharma stock Monday?
April 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/what-s-going-on-with-sonoma-pharma-stock-monday/ar-AA21PdPx
Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering
April 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/sonoma-pharmaceuticals-announces-pricing-4-132100121.html
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 14 at 1:00 AM  |  American Alternative (Ad)
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart
March 24, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68022819-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-announces-u-s-retail-launch-of-advanced-burn-relief-hydrogel-in-cvs-and-walmart-200.htm
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
February 10, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67666437-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-reports-third-fiscal-quarter-2026-financial-results-200.htm
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
January 29, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-01/67552599-sonoma-pharmaceuticals-inc-sonoma-pharmaceuticals-welcomes-new-member-of-its-board-of-directors-and-new-senior-vice-president-of-regulatory-qualit-200.htm
See More Sonoma Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sonoma Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sonoma Pharmaceuticals and other key companies, straight to your email.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals (NASDAQ:SNOA) is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases. This approach is designed to enhance efficacy while minimizing skin irritation. The company’s lead product, Azclear® Foaming Gel, leverages azelaic acid to address papulopustular rosacea, and is complemented by additional prescription formulations and a suite of over-the-counter cleansers and medicated washes targeting acne-prone skin.

Headquartered in Santa Rosa, California, Sonoma Pharmaceuticals distributes its dermatology portfolio through physician offices, retail pharmacies and online channels across the United States. Under the leadership of President and Chief Executive Officer Mark D. Sirgo, the company is advancing its clinical pipeline and exploring strategic collaborations to expand its product offerings and reach new patient populations.

View Sonoma Pharmaceuticals Profile
Earnings Tools